吡贝地尔
化合物
此条目可参照英语维基百科相应条目来扩充。 (2024年4月5日) |
吡贝地尔(INN:piribedil)是一种抗帕金森病药物和哌嗪衍生物,可作为D2和D3受体激动剂。它还具有α2-肾上腺素受体拮抗剂特性。[2][3]
![]() | |
![]() | |
临床资料 | |
---|---|
AHFS/Drugs.com | 国际药品名称 |
给药途径 | 口服 |
ATC码 | |
法律规范状态 | |
法律规范 |
|
药物动力学数据 | |
生物利用度 | 10%(1小时高峰) |
血浆蛋白结合率 | 70–80% |
药物代谢 | 广泛肝 |
生物半衰期 | 1.7至6.9小时 |
排泄途径 | 肾(68%)和胆管(25%) |
识别信息 | |
| |
CAS号 | 3605-01-4 ![]() |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.695 |
化学信息 | |
化学式 | C16H18N4O2 |
摩尔质量 | 298.35 g·mol−1 |
3D模型(JSmol) | |
| |
|
参考资料
- ^ Active substance: piribedil (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020.
- ^ Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. The Journal of Pharmacology and Experimental Therapeutics. June 2001, 297 (3): 876–887 [2024-04-05]. PMID 11356907. (原始内容存档于2019-12-14).
- ^ Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. The Journal of Pharmacology and Experimental Therapeutics. April 2003, 305 (1): 338–346. PMID 12649387. S2CID 29234876. doi:10.1124/jpet.102.046383.